Fundz
Following Lotte Biologics?

Get the free weekly contract digest

The latest new contracts, like Lotte Biologics’s — who’s behind them and what they mean, delivered to your inbox every week. No credit card, unsubscribe anytime.

Weekly Digest

New new contracts, summarized for you

Straight to Inbox

No login, no app to check — it comes to you

Contract Trends

See who's moving and how much in your market

No credit card required Weekly contract digest

Lotte Biologics partners with Asimov for CDMO collaboration in US

Mar 13, 2025•over 1 year ago

Contract Type

partnership

SeoulManufacturingBiotechnologyBiopharma

Description

Lotte Biologics has signed a memorandum of understanding (MOU) for collaboration in the contract development and manufacturing organization (CDMO) business with Asimov, based in Boston, Massachusetts. With this agreement, Lotte Biologics plans to provide comprehensive services from cell line development to GMP (Good Manufacturing Practice) production utilizing Asimov's next-generation cell line development platform technology.

Company Information

Company

Lotte Biologics

Location

Seoul, Seoul, South Korea

About

Lotte Biologics is a rapidly expanding contract development and manufacturing business with a dual-track strategy of acquisitions and new construction. The company focuses on biologics manufacturing and has operations in various locations including Syracuse, New York and Songdo, Incheon.

Related People

Suggested for you

Choose your plan to reveal verified contacts

Choose your plan to reveal verified contacts

Predictive Intelligence
Strategic

ML-powered predictions for Lotte Biologics's next move

Learn about Strategic plan

Agreement Insights

Based on industry data
Strategic partnership established
Partnership agreements typically involve technology integration and joint go-to-market strategies
Contract momentum indicator
Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals — including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications — based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 200,000+ companies. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.